Provider review
Shed Review: It Quotes the Placebo Arm, Then Sells a Peptide With No Trial
Shed does something almost no seller does: it quotes the placebo arm. Its GLP-1 claim reads that with Zepbound and Wegovy "the average weight loss was 15% and 20%, respectively, when paired with diet and exercise (compared to 2.4% and 3.1% with diet and exercise alone)" — correct figures, the lifestyle arm named, and the compounded-drugs disclaimer attached to it. Its NAD+ FAQ refuses to promise a timeline. Its sex-health line puts bremelanotide under "For Women", which is where the evidence for that molecule actually is. And then its longevity range sells sermorelin at $199 a month, a molecule with no ClinicalTrials.gov record naming it as an intervention and no randomised-trial publication anywhere, described as appealing to people who want "a safer, more natural alternative to synthetic growth hormone therapy" — a comparative safety claim nobody has tested.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.tryshed.com. A link is not a recommendation to take anything.
Provenance
What Shed actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin Injection — $199 a month for a one-month supply, taken five times weekly. No plan-length discount is published for it.
- NAD+ Rx (injection, tablet or nasal spray) — "From $144/mo", offered as an injection, a tablet or a nasal spray, with the route chosen by the provider.
- Glutathione Rx Injection — Listed in the longevity range without a rendered price; the figure appears inside the signup portal.
- Desire Rx (sublingual tablet, for women) — Listed without a rendered price; the figure appears inside the signup portal.
- Compounded Semaglutide Injections — Advertised "From $159/mo"; the walk-away figure verified on the sibling cost site is $199 a month, billed monthly. A "lose 5% in 120 days or your money back" guarantee is offered, subject to published terms.
- Compounded Tirzepatide Injections — Advertised "From $239/mo"; the verified walk-away figure is $299 a month, billed monthly.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
4
Products with a human trial
Out of 6 reviewed here.
6
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Shed’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Sermorelin InjectionSermorelin · Compounded (503A)Claim reaches past the trials
“Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to naturally produce more growth hormone (GH). Unlike synthetic GH injections, which introduce GH directly, Sermorelin works with the body's natural feedback mechanisms, promoting a more balanced and controlled increase in GH levels. […] it appeals to those seeking a safer, more natural alternative to synthetic growth hormone therapy, particularly for its potential anti-aging and metabolic benefits.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six query forms were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies returned are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified diagnostic "GHRH". In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO carry the randomised-controlled-trial or clinical-trial publication type. The searches discriminate: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
The mechanism is described accurately and with real care — sermorelin is a GHRH analogue, it does act on the pituitary, and working through the body's own feedback loop genuinely is different from administering growth hormone. Shed also publishes a proper contraindication list, naming active cancer, pituitary disorders, pregnancy and diabetes, and gives an actual dose range (100–300 mcg) and schedule, which most competitors omit. The claim that reaches past the evidence is "a SAFER, more natural alternative to synthetic growth hormone therapy": safety is comparative, no trial has compared the two, and there is no completed human trial of sermorelin at all. Shed softens it — "appeals to those seeking", "potential anti-aging and metabolic benefits" — which is why this is graded as reaching past the trials rather than unsupported.1,2
NAD+ Rx (injection, tablet or nasal spray)NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)Claim matches the trials
“NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found naturally in the body. It plays a role in normal cellular processes, including energy production and metabolic function. NAD+ levels naturally change with age and lifestyle factors, which has been linked to fatigue, cognitive slowdown, and metabolic inefficiencies. […] When will I start to notice changes? Responses vary for everyone. Some people notice changes early on, while some may not notice significant changes. The purpose of NAD+ is to support normal cellular processes over time.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomised trial supporting a restoration-of-function claim, and no registered study measures a cognitive endpoint for NAD+ by any route. A PubMed search for "nicotinamide adenine dinucleotide" combined with injection, subcutaneous or nasal, filtered to the randomised-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Graded as matching because Shed confines itself to what is actually true of the molecule and declines the three moves its competitors make. It calls NAD+ a coenzyme — correct, where one seller in this wave calls it a peptide that signals the pituitary. It says levels "naturally change with age", which "HAS BEEN LINKED TO" fatigue and cognitive slowdown — a correlation stated as a correlation. And asked when a patient will notice changes, it answers that some people may not notice significant changes at all, where two competitors publish month-by-month schedules of results. ⚠ The unstated gap remains and is the same everywhere: no completed human trial of injected or intranasal NAD+ exists, and the page does not say that the real evidence concerns oral precursors by a different route.3
Glutathione Rx InjectionGlutathione · Compounded (503A)Claim matches the trials
“Glutathione Rx — Injection · antioxidant support.”
Phase 1 only
- NCT01355198 — Phase 1, completed, n=10. Ten participants, glutathione synthesis and oxidative stress in HIV infection.
- NCT02348775 — Phase 1, completed, n=16. Sixteen participants, glutathione and function in HIV patients. Together these are effectively the whole injected-glutathione adult record.
Shed says almost nothing about this product — four words, "Injection · antioxidant support" — and glutathione genuinely is an antioxidant, so there is no overstatement to grade. That restraint is the honest response to a thin evidence base. ⚠ The base is very thin: of 200 glutathione intervention records on ClinicalTrials.gov, only four involve an injected or intravenous route, and the two studying it in adults are phase 1 trials enrolling ten and sixteen people, both about oxidative stress in HIV infection. Nothing in that literature speaks to a wellness or longevity purchase, and Shed does not claim it does.4
Desire Rx (sublingual tablet, for women)Bremelanotide (PT-141) with oxytocin · Compounded (503A)Claim reaches past the trials
“For Women — Desire Rx: Sublingual tablet · libido support (Oxytocin / Bremelanotide).”
Phase 3 trials
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Bremelanotide in premenopausal women with hypoactive sexual desire disorder — the population Shed lists it under.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The second registration trial, same population.
Shed places bremelanotide under "For Women", which is the correct population and is more than most of this roster manages — three sellers in this series put the same molecule in a men's performance line, against a label whose Limitations of Use exclude both men and performance enhancement. Two things still reach past the evidence. The approved product is a subcutaneous AUTOINJECTOR; Shed dispenses a SUBLINGUAL tablet, and no registered trial tested bremelanotide by that route. And it is combined with oxytocin, for which no trial of the combination exists at all. "Libido support" is a mild claim, but it is being made for a formulation and a route that RECONNECT did not test.5,6
Compounded Semaglutide InjectionsSemaglutide · Compounded (503A)Claim matches the trials
“With Zepbound® (15 mg) and Wegovy® (2.4 mg), the average weight loss was 15% and 20%, respectively, when paired with diet and exercise (compared to 2.4% and 3.1% with diet and exercise alone). Results may vary. Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription. […] Lose 5% of your weight in 120 days or your money back.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks, with lifestyle intervention in every arm — roughly 14.9% from baseline against 2.4% on placebo.
This is one of the two best-stated GLP-1 claims in the entire review series, and the reason is the parenthesis. Shed reports the comparator — "compared to 2.4% and 3.1% with diet and exercise alone" — which is the number marketing copy almost always drops, because keeping it shows how much of the result is the drug rather than the programme. It also names the approved products the figures belong to, says the results were obtained "when paired with diet and exercise", adds "results may vary", and attaches the compounded disclaimer in the same block. ⚠ It does not name the trials themselves, and the standing caveat applies unstated: those figures are the approved products', not the compounded preparation Shed dispenses.7
Compounded Tirzepatide InjectionsTirzepatide · Compounded (503A)Claim matches the trials
“With Zepbound® (15 mg) and Wegovy® (2.4 mg), the average weight loss was 15% and 20%, respectively, when paired with diet and exercise (compared to 2.4% and 3.1% with diet and exercise alone). Results may vary. Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide at the highest tolerated dose over 72 weeks, with lifestyle intervention in every arm.
The same carefully constructed sentence covers tirzepatide, and it maps correctly: the 20% figure belongs to Zepbound at 15 mg, against a 3.1% lifestyle-only comparator. Naming both approved products and both placebo arms in one sentence, with the compounded disclaimer attached, is the most complete GLP-1 statement any company in this series publishes. Same unstated caveat: SURMOUNT-1 tested the approved product, not a compounded preparation.8
Dispensing chain
Who actually fills your prescription
Read the full account
No dispensing pharmacy is named anywhere on the site. What Shed does state, and states in the right place — inside the same block as its efficacy figures rather than in a terms page — is the regulatory position: "Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription." That single sentence carries both facts a compounded-drug buyer most needs: no FDA approval, and a prescription-and-pharmacy pathway. Two other companies in this review series hold open FDA warning letters for omitting the first half of it. ⚠ What is withheld is the identity: which licensed pharmacy, where, and reachable how. A patient who wanted a lot record would have nobody to ask. ⚠ Shed is unusually specific about the product itself in compensation — its sermorelin page publishes an actual dose range (100–300 micrograms), an administration route and schedule (subcutaneous, at night, five times weekly, timed to the body's growth-hormone cycle), and a real contraindication list naming active cancer, pituitary disorders, pregnancy and breastfeeding, and diabetes or insulin resistance. That is more clinical detail than most of this roster publishes, and it is not a substitute for knowing who made the vial.
Read on August 2026 from https://www.tryshed.com/products/sermorelin
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product, and no pharmacy is named to ask. ⚠ Set against that, Shed publishes two things most of this category does not. Its efficacy block carries the sentence "Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription" — attached to the claim rather than buried. And its product pages carry genuine clinical content: a dose range and schedule for sermorelin, a route choice for NAD+ (injection, tablet or nasal spray) stated as the provider's decision, and side-effect lists that name warmth or flushing, mild nausea, headache and lightheadedness rather than omitting them. ⚠ It cites no study, trial identifier or publication anywhere — its GLP-1 figures are correct and accurately reported, but a reader is not told which trials they come from and cannot check them without knowing to look for STEP 1 and SURMOUNT-1.
Read on August 2026 from https://www.tryshed.com/products/nad
Licensing
Licensed to dispense, and where
Coverage
All 50 states, the District of Columbia and Puerto Rico
Read the full licensing claim
Taken from data rather than from a marketing claim: Shed's own signup portal carries a 52-entry state table covering all fifty states, the District of Columbia and Puerto Rico, and the same bundle carries a `disqualifiedStates` list which is EMPTY — so there is no jurisdiction the portal itself turns away. `statesExcluded` is therefore empty as a matter of evidence rather than of silence. ⚠ Puerto Rico is a territory rather than a state, and an earlier pass in this network marked a provider down for exactly that distinction; the coverage question here is whether a patient can be served, and the answer is yes everywhere the portal reaches. No individual clinician is named and no licence number is published, and the site does not state which medical group employs its prescribers.
Read on August 2026 from https://www.tryshed.com
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It quotes the placebo arm. Its GLP-1 claim reports 15% and 20% "compared to 2.4% and 3.1% with diet and exercise alone" — the comparator almost every competitor drops.
- It states that the results were obtained "when paired with diet and exercise", where three sellers in this series describe the same drugs as producing effortless weight loss.
- "Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription" sits in the same block as the efficacy figures, not in a terms page.
Show 8 more
- Its NAD+ FAQ refuses to promise a timeline: "Some people notice changes early on, while some may not notice significant changes."
- It calls NAD+ a coenzyme and describes the age link as something that "has been linked to" fatigue — a correlation stated as a correlation.
- It places bremelanotide under "For Women", which is the population the trials actually studied.
- Its sermorelin page publishes a real dose range (100–300 mcg), route, timing and a proper contraindication list naming cancer, pituitary disorders, pregnancy and diabetes.
- Coverage comes from a 52-entry state table in its own portal — all 50 states, DC and Puerto Rico — with an empty disqualified-states list.
- NAD+ is offered as an injection, a tablet or a nasal spray, with the route presented as a clinical decision rather than an upsell.
- A "lose 5% of your weight in 120 days or your money back" guarantee is offered, with terms published.
- No FDA warning letter — screened against the live index on the trading name with a positive control that fired.
- Sermorelin at $199 a month has no ClinicalTrials.gov record naming it as an intervention and no randomised-trial publication under any name.
- It is described as appealing to those seeking "a safer, more natural alternative to synthetic growth hormone therapy" — a comparative safety claim no trial has tested.
- No dispensing pharmacy is named anywhere, so despite the honest "licensed pharmacy" disclosure there is nobody a patient can ask for a lot record.
Show 7 more
- No certificate of analysis, lot number, potency or sterility result is published for any product.
- Injected and intranasal NAD+, from $144 a month, have no completed human trial, and the page does not mention that the real evidence concerns oral precursors by a different route.
- "Desire Rx" is a SUBLINGUAL bremelanotide tablet combined with oxytocin. The approved product is a subcutaneous autoinjector, and no trial tested that route or that combination.
- Injected glutathione's entire adult human record is two phase 1 studies totalling twenty-six people with HIV.
- No study, trial identifier or publication is cited anywhere, so its correct GLP-1 figures cannot be traced from the page.
- No prescribing clinician is named, no licence number is published, and the medical group behind the prescribers is not identified.
- Several longevity products — glutathione, methylene blue, low-dose naltrexone, Desire Rx — render no price at all outside the signup portal.
Verdict
The bottom line
Shed writes about GLP-1s better than almost anyone in this roster and sells peptides on the same terms as everyone else. Its weight-loss claim quotes both placebo arms, names the approved products the figures belong to, says the results came alongside diet and exercise, and attaches the not-FDA-approved disclaimer in the same breath — a standard two companies in this series have open FDA warning letters for failing to meet. Its NAD+ page calls the molecule a coenzyme, describes the age link as a link, and tells patients some of them may notice nothing. Then the longevity range sells sermorelin at $199 a month for a molecule with no human trial under any name, on a comparative safety claim, and no pharmacy is named anywhere on the site. If you are buying a GLP-1 here, the numbers you are being shown are the real ones and the caveats are on the same page. If you are buying the peptide, you are getting the same absent evidence as everywhere else, described more carefully.
Opens www.tryshed.com. A link is not a recommendation to take anything.
The number nobody else prints
Here is Shed's weight-loss claim, in full:
"With Zepbound® (15 mg) and Wegovy® (2.4 mg), the average weight loss was 15% and 20%, respectively, when paired with diet and exercise (compared to 2.4% and 3.1% with diet and exercise alone). Results may vary. Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription."
Four things in that sentence are unusual enough to name individually.
It reports the placebo arm. 2.4% and 3.1% are what the comparison groups lost on diet and exercise alone, and quoting them is the single most informative thing a seller can do — because it shows how much of the headline belongs to the drug rather than to the programme wrapped around it. 7 8 Marketing copy almost always drops it.
It names which products the figures belong to — Zepbound at 15 mg and Wegovy at 2.4 mg — rather than implying they were obtained with the compounded preparation Shed actually dispenses.
It says the results came "when paired with diet and exercise". Three sellers in this same review series describe the identical drugs as producing "effortless" weight loss.
And it attaches the compounded disclaimer to the claim, in the same block, rather than in a terms page nobody opens. Two companies in this series are under open FDA warning letters for exactly the omission Shed avoids here.
The one thing it does not do is name the trials. The figures come from STEP 1 and SURMOUNT-1, and a reader who wanted to check them would have to already know that.
Full analysis — 5 more sectionsThe longevity range, where the care runs out · Where Shed gets NAD+ right · The right population, the wrong route · Who makes it · What this means if you are buying
The longevity range, where the care runs out
Shed's longevity line is Microdose GLP-1, glutathione, methylene blue, NAD+, low-dose naltrexone and sermorelin.
Sermorelin is $199 a month, taken five times weekly. Shed describes it well:
"Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to naturally produce more growth hormone… Unlike synthetic GH injections, which introduce GH directly, Sermorelin works with the body's natural feedback mechanisms."
All true. And it publishes real clinical detail almost nobody else does: a dose range of 100–300 micrograms, subcutaneous administration at night to align with the body's growth-hormone cycle, and a contraindication list naming active cancer, pituitary disorders, pregnancy and breastfeeding, and diabetes or insulin resistance.
Then this:
"it appeals to those seeking a safer, more natural alternative to synthetic growth hormone therapy, particularly for its potential anti-aging and metabolic benefits."
Safer is a comparative clinical claim. No trial has compared sermorelin with growth hormone, because no trial of sermorelin exists.
A ClinicalTrials.gov search returns no interventional record naming sermorelin as the intervention, across six query forms including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name, plus a free-text pass over every field. 1 The 27 studies returned are other molecules — mostly tesamorelin and GHRH(1-44). PubMed holds 24 mentions and zero with a randomised-trial publication type. 2 Controls in the same pass returned 158 registry records for tirzepatide, 17 for tesamorelin, 10 for bremelanotide.
Shed hedges it — "appeals to those seeking", "potential" benefits — which is why this reads as a claim reaching past its evidence rather than a fabrication. It is still the one sentence on the page a buyer should not rely on.
Where Shed gets NAD+ right
Its NAD+ line, from $144 a month, is offered as an injection, a tablet or a nasal spray, with the route presented as the provider's decision.
The copy is careful in three specific ways. It calls NAD+ "a coenzyme found naturally in the body" — correct, where a competitor in this wave heads its NAD+ page "a peptide that signals your own pituitary gland". It says levels change with age "which has been linked to fatigue, cognitive slowdown, and metabolic inefficiencies" — a correlation described as a correlation rather than as a mechanism of action.
And asked the question every buyer asks, it declines to answer:
"When will I start to notice changes? Responses vary for everyone. Some people notice changes early on, while some may not notice significant changes."
Two competitors in this series publish month-by-month schedules of expected results for peptides with no trials at all. Telling a prospective customer they might notice nothing is the opposite of that.
What Shed does not say is that there is no completed human trial of injected or intranasal NAD+ at all, and that the substantial human literature is about oral precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules taken a different way. 3
The right population, the wrong route
Shed's sex-health range lists, under For Women:
"Desire Rx — Sublingual tablet · libido support (Oxytocin / Bremelanotide)"
Putting bremelanotide in a women's line is correct and unusual. Its two phase 3 trials, RECONNECT 1 and 2, enrolled 723 and 714 premenopausal women with hypoactive sexual desire disorder, and the approved product's label carries Limitations of Use excluding men and performance enhancement. 5 6 Three other sellers in this series put the same molecule in a men's performance line.
Two things still do not match the trials. The approved product is a subcutaneous autoinjector; Shed's is a sublingual tablet, and no registered trial tested bremelanotide by that route. And it is combined with oxytocin, for which no trial of the combination exists.
Who makes it
Nobody named. Shed says its medications are "made by a licensed pharmacy based on a provider's prescription" — honest as far as it goes, and it goes no further. No pharmacy name, no address, no phone number.
That matters practically. There is no certificate of analysis, lot number, potency or sterility result published for any product — which is true of every company in this roster — but here there is also nobody to ask, because the party holding those records is never identified.
No prescribing clinician is named either, and no medical group is identified.
On coverage Shed is better than its peers, and the evidence is data rather than a slogan: its own signup portal carries a 52-entry state table — all fifty states, the District of Columbia and Puerto Rico — and the accompanying disqualified-states list is empty. There is no jurisdiction the portal turns away.
What this means if you are buying
For a GLP-1, Shed is one of the better-documented options in this roster. The figures it shows you are real, the placebo comparison is right there, and the compounded disclaimer is attached to the claim rather than hidden. Budget $199 a month for semaglutide and $299 for tirzepatide rather than the "from" prices, and read the terms on the 120-day guarantee before relying on it.
For sermorelin, know that the careful clinical detail on the page — the dose range, the timing, the contraindications — sits on top of a molecule with no human trial under any name, and that "safer than growth hormone" is a comparison nobody has run.
For NAD+, the page is honest about what it does not know. It just does not tell you that the evidence which exists is for a different molecule taken a different way.
And for anything here: ask which pharmacy is making it, because the website will not tell you.
Questions
Frequently asked questions
Are Shed's weight-loss figures accurate?
Yes, and they are among the best-stated in this review series. Shed writes that with Zepbound (15 mg) and Wegovy (2.4 mg) "the average weight loss was 15% and 20%, respectively, when paired with diet and exercise (compared to 2.4% and 3.1% with diet and exercise alone)". Those figures match the trials, and the parenthesis is the important part: it reports the comparator arms, which shows how much of the result belongs to the drug rather than to the diet-and-exercise programme every participant received. It also names the approved products the figures belong to, adds "results may vary", and attaches "Compounded medications are not FDA-approved and are made by a licensed pharmacy based on a provider's prescription" in the same block. The one omission: it does not name the trials, so a reader cannot trace the numbers without already knowing to look for STEP 1 and SURMOUNT-1.
Is there evidence for Shed's sermorelin?
No registered trial names the molecule. A ClinicalTrials.gov search on 10 August 2026 returned no interventional record naming sermorelin as the intervention across six query forms — including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name — plus a free-text search of every field; the 27 studies returned are other molecules, mostly tesamorelin. PubMed holds 24 mentions and none with a randomised-trial publication type. Controls fired in the same pass: 158 registry records for tirzepatide, 17 for tesamorelin, 10 for bremelanotide. Shed describes the mechanism accurately and publishes unusually good clinical detail — a 100–300 mcg dose range, night-time subcutaneous dosing, and contraindications naming cancer, pituitary disorders, pregnancy and diabetes. The claim to treat carefully is that it is "a safer, more natural alternative to synthetic growth hormone therapy": safety is comparative, and no trial has compared them.
Which pharmacy does Shed use?
It does not say. Shed states that its medications are "made by a licensed pharmacy based on a provider's prescription", which is an honest description of the pathway and is placed well — in the same block as its efficacy figures rather than in a terms page. But no pharmacy is named, no address or phone number is given, and no prescribing clinician or medical group is identified. The practical consequence is that Shed publishes no certificate of analysis, lot number, potency or sterility result — true of every company in this roster — and here there is also nobody to ask for one.
Does Shed serve my state?
Almost certainly. This comes from Shed's own data rather than a marketing claim: the signup portal carries a 52-entry state table covering all fifty states, the District of Columbia and Puerto Rico, and the accompanying disqualified-states list is empty — so there is no jurisdiction the portal itself turns away. Worth noting for anyone comparing scores across sites: Puerto Rico is a territory rather than a state, and a provider should not be marked down for including it.
Is Shed's bremelanotide product the same as the approved one?
Same molecule, different route and different formulation. Shed lists "Desire Rx" under For Women as a sublingual tablet combining oxytocin and bremelanotide, and putting it in a women's line is correct — bremelanotide's two phase 3 trials enrolled 723 and 714 premenopausal women with hypoactive sexual desire disorder, and the approved product's label carries Limitations of Use excluding men and performance enhancement. Three other sellers in this review series place the same molecule in a men's performance line. Two differences from the trials remain: the approved product is a subcutaneous autoinjector and Shed's is sublingual, a route no registered trial tested; and it is combined with oxytocin, for which no trial of the combination exists.
Glossary
Key terms
Show definitions
- Placebo arm
- The comparison group in a trial, which receives everything except the active drug. Reporting it is how a reader tells how much of a headline result belongs to the medicine rather than to the diet and exercise programme every participant received. Shed reports it; most sellers do not.
- Sermorelin
- A synthetic fragment of growth hormone-releasing hormone, GHRH(1-29), which signals the pituitary to release the body's own growth hormone. Once approved in the US as Geref; that approval has been withdrawn, and no current ClinicalTrials.gov record names sermorelin as an intervention.
- Sublingual
- Dissolved under the tongue rather than injected. It is a different route with different absorption, and a trial of an injected product is not evidence for a sublingual one.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Shed's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 8 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six query forms run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. Positive controls in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed: "sermorelin"[tiab] returns 24 records; with the randomised-controlled-trial publication type, 0. Controls: tirzepatide 126, tesamorelin 21, bremelanotide 11. Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected and intranasal NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim, and no registered study reporting a cognitive endpoint by any route. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- US National Library of Medicine (2026). Injected glutathione in humans — of 200 glutathione intervention records, only four involve an injected or intravenous route, and the two studying it in adults are NCT01355198 (phase 1, n=10) and NCT02348775 (phase 1, n=16), both on oxidative stress in HIV infection. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=glutathione
- US National Library of Medicine (2026). RECONNECT Study 1 (NCT02333071, phase 3, completed, n=723) — bremelanotide in premenopausal women with hypoactive sexual desire disorder. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02333071
- US National Library of Medicine (2026). RECONNECT Study 2 (NCT02338960, phase 3, completed, n=714) — the second bremelanotide registration trial, same population. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02338960
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.